Rosuvastatin calcium is chemically, bis\[(E)-7\[4-(4-fluorophenyl)-6-isopropyl-2-\[methyl (methyl-sulphonyl)amino\]pyrimidin-5-yl\](3R,5S)-3,5-dihydroxyhept-6-enoic acid\] calcium salt ([fig. 1](#F1){ref-type="fig"}). It belongs to a class of drugs called statins, which are employed to lower hypercholesterolemia and related conditions and to prevent cardiovascular diseases. It increases the number of hepatic low density lipoprotein receptors involved in the catabolism of LDL and also inhibits hepatic synthesis of very low density lipoprotein\[[@ref1]--[@ref3]\].

![Structure of rosuvastatin calcium](IJPhS-72-592-g001){#F1}

A detailed survey of analytical literature for rosuvastatin revealed few methods based on a variety of techniques such as UV-spectrophotometry\[[@ref4]\], high performance thin layer chromatography (HPTLC)\[[@ref5]\] and HPLC\[[@ref6][@ref7]\]. Since a HPLC method has many advantages over that of a HPTLC method for quantitation, HPLC is often the first choice for developing an analytical method as compared to HPTLC. Till date, none of the reported analytical procedure describe a simple, satisfactory and validated HPLC method for studying the effect of stress on pharmaceutical dosage forms as well as for assay and determination of content uniformity of rosuvastatin calcium in tablet dosage forms. [Table 1](#T1){ref-type="table"} shows comparison of published methods with the developed method.

###### 

COMPARISON OF PUBLISHED METHODS WITH DEVELOPED METHOD

![](IJPhS-72-592-g002)

The objective of this work was to develop a simple, precise, reliable and rapid stability-indicating liquid chromatographic analytical method for assay of rosuvastatin calcium and for determination of the content uniformity of a tablet formula-tion, to validate the method in accor-dance with ICH\[[@ref8]\] guidelines. The validation procedure followed the guidelines of USP 30\[[@ref9]\]. The method was successfully used for the assay of rosuvastatin calcium and determination of the content uniformity in the tablet formulation. Determination of content uniformity is nowadays, an important test included in USP 30\[[@ref9]\]. Since there is no literature report of a validated analytical method for determination of the content unifor-mity of rosuvastatin calcium in pharmaceutical dos-age forms (10 mg) this was performed in the current work.

MATERIALS AND METHODS {#sec1-1}
=====================

Rosuvastatin calcium reference standard (label claim 99.8% pure) was provided by Glenmark Pharmaceuticals Ltd., Ankleshwar, India. Tablets of rosuvastatin calcium, Zyrova, with a 10 mg label claim, manufactured by Zydus Cadila, Ahmedabad, India were procured from a local pharmacy. HPLC grade acetonitrile and orthophosphoric acid were obtained from Merck India Limited, Mumbai, India. Analytical grade hydrochloric acid, sodium hydroxide pellets and hydrogen peroxide solution 30% (v/v) were obtained from Ranbaxy Fine Chemicals, New Delhi, India and 0.45 μm membrane filter was obtained from Pall Life Sciences, Mumbai, India. High purity deionised water was obtained from a Milli-Q (Millipore, Milford, MA, USA) purification system.

Chromatography: {#sec2-1}
---------------

The chromatographic system used to perform development and validation of this assay method consisted of an LC-10AT*vp* binary pump, an SPD-M10Avp photodiode array detector and a Rheodyne manual injector model 7725i with 20 μl loop (Shimadzu, Kyoto, Japan) connected to a multi-instrument data acquisition and data processing system (Class-*VP* 6.13 SP2, Shimadzu). Chromatographic analysis was performed on YMC C8 (150?4.6 mm id, 5 μm particle size) column. Separation was achieved using a mobile phase consist of acetonitrile-water (40:60, v/v) solution at a flow rate of 1.5 ml/min. The eluent was monitored using PDA detector at a wavelength 242 nm. The column was maintained at ambient temperature and injec-tion volume of 20 μl was used. The mobile phase was filtered through 0.45 μm filter prior to use.

Preparation of stock, standard and test solutions: {#sec2-2}
--------------------------------------------------

Stock solution (500 μg/ml) of rosuvastatin calcium reference standard was pre-pared by transferring 25 mg, accurately weighed, into a 50 ml volumetric flask and adding 20 ml water- acetonitrile (50:50, v/v). The mixture was sonicated for 2 min to dissolve the rosuvastatin calcium and the solution was then diluted to volume with the same solvent mixture. Standard solution (50 μg/ml) was prepared by diluting 5 ml stan-dard stock solution to 50 ml, in a volumetric flask, with the same solvent mixture.

To prepare stock solution (500 μg/ml) for assay, 20 tablets were weighed and mixed. An aliquot of powder equivalent to the weight of 5 tablets was accurately weighed and transferred to 100 ml volumetric flask. Water-acetonitrile (50:50, v/v), 60 ml was added to the flask and the mixture was sonicated for 10 min with normal hand shaking. The contents of the flask were then left to return to room temperature and diluted to volume with the same solvent mixture. This solution (10 ml) was filtered through a 0.45-μm nylon syringe filter.

To prepare test solution (50 μg/ml) for assay 5 ml test stock solution was transferred to 50 ml volumetric flask and diluted to volume with water-acetonitrile (50:50, v/v). To prepare test solution (50 μg/ml) for determination of content uniformity one tablet was accurately weighed and transferred to a 200-ml volumetric flask. Water-acetonitrile (50:50, v/v) 100 ml was added to the flask and the mixture was sonicated for 10 min with normal hand shaking. The contents of the flask were left to return to room temperature, then diluted to volume with the same solvent mixture and filtered through a 0.45 μm nylon syringe filter. Twenty tablets were weighed and the average weight of a tablet was used for assay calculation.

Method validation: {#sec2-3}
------------------

In the developed method, by using same concentration of analyte for the assay and for determination of content uniformity, both methods could be validated simultaneously except for determination of precision. The specificity of the method was evaluated to ensure there was no interference from placebo components (prepared in solution) or from products resulting from forced degradation.

Forced degradation studies\[[@ref10]\]: {#sec2-4}
---------------------------------------

To perform the forced degradation study 50 mg drug was subjected to acidic, alkaline, oxidizing, thermal and photolytic conditions. For acidic degradation the drug was heated under reflux with 0.1 M HCl at 80º for 2 h and the mixture was neutralized. For alkaline degradation the drug was treated with 0.1 M NaOH at 80º for 2 h and the mixture was neutralized. For degradation under oxidizing conditions the drug was heated under reflux with (6%, v/v) H~2~O~2~ at 80º for 2 h. For thermal degradation the powdered drug was exposed at 70º for 48 h. For photolytic degra-dation the powdered drug was exposed to sunlight for 48 h. The placebo was also subjected to the same stress con-ditions to determine whether any peaks arose from the declared excipients. After completion of the treatments the solutions were left to return to room temperature and diluted with water-acetonitrile (50:50, v/v) to furnish 50 μg/ml solutions. The purity of the drug peak obtained from the stressed sample was measured using PDA detector. [Fig. 2](#F2){ref-type="fig"} shows the chromatogram of untreated drugs in tablet solution.

![Chromatogram of untreated drugs in tablet solution (50 μg/ml).](IJPhS-72-592-g003){#F2}

Linearity: {#sec2-5}
----------

Eight solutions were prepared containing 0.5, 20, 30, 40, 50, 60, 70 and 80 μg/ml rosuvastatin calcium, concentrations which corresponded to 1, 40, 60, 80, 100, 120, 140 and 160%, respectively, of the test solution concentration. Each solution was injected in duplicate. Linearity was evaluated by linear-regression analysis.

Precision: {#sec2-6}
----------

System precision was evaluated by analyzing the standard solution five times and method precision (repeatability) was evaluated by assaying six sets of test samples prepared for assay determination and ten sets of samples prepared for determination of content uniformity, all on the same day (intra-day precision). System precision and method precision were also determined by performing the same procedures on a different day (inter-day precision), and by another person under the same experimental conditions (intermediate precision).

Accuracy: {#sec2-7}
---------

Accuracy was assessed by determination of the recovery of the method at three different concentrations (corresponding to 50, 100 and 150% of test solution concentration) by addition of known amounts of standard to placebo preparation. For each concentration, three sets were prepared and injected in duplicate.

Robustness: {#sec2-8}
-----------

The robustness of the method was evaluated by assaying test solutions after slight but deliberate changes in the analytical conditions. The factor chosen for this study were the flow rate (±0.1 ml/min), mobile phase composition (acetonitrile-water, 38:62 and 42:58, v/v) and using a different batch of HPLC column.

Solution stability: {#sec2-9}
-------------------

Stability in solution was evaluated for the standard solution and the test preparation. The solutions were stored at 5º and at ambient temperature without protection of light and tested after 12, 24, 36 and 48 h. The responses for the aged solution were evaluated by comparison with freshly prepared solutions.

System suitability: {#sec2-10}
-------------------

The suitability of the chromatographic system was tested before each stage of validation. Five replicate injections of standard preparation were injected and asymmetry, number of theoretical plates and relative standard deviation of peak area were determined.

RESULTS AND DISCUSSION {#sec1-2}
======================

In this work an analytical HPLC method for assay and determination of content uniformity of rosuvastatin calcium in a tablet for-mulation was developed and validated. The basic chromatographic conditions were designed to be simple and easy to use and reproduce and were selected after testing the different conditions that affect HPLC analysis, for example column, aqueous and organic components of the mobile phase, proportion of mobile phase components, detection wavelength, diluents and concentration of analyte. The YMC Pack C8 column was used because of its advantages of high resolving capacity, better reproducibility, low-back pressure, and low tailing. For mobile phase selection, preliminary trials using mobile phases of different composition containing water adjusted to acid pH by addition of orthophosphoric acid and methanol resulted in poor peak shape. When methanol was replaced by acetonitrile better peak shape was obtained. The proportion of the mobile phase components was optimized to reduce retention times and enable good resolution of rosuvastatin calcium from the degradation products. A detection wavelength of 242 nm was selected after scanning the standard solution over the range 190-370 nm by use of the PDA detector. Detection at 242 nm resulted in good response and good linearity.

The drug substance was easily extracted from the pharmaceutical dosage form using water-acetonitrile (50:50, v/v). The tablet dispersed readily in water and the drug substance was freely soluble in acetonitrile. Solutions of standard and test preparations were found to be stable in this solvent mixture. By using the same concentration of analyte for assay and for determination of content uniformity both methods could be validated simultaneously except for determination of precision.

After development of the analytical method, it was validated in accordance with ICH\[[@ref8]\] and USP\[[@ref9]\] guidelines. This furnished evidence the method was suitable for its intended purpose. The specificity of the method was determined by checking for interference with the drug from placebo components. The specificity of the method was also evaluated by checking the peak purity of the analyte peak during the forced degradation study. The peak purity of the rosuvastatin peak under different stress conditions was 1.00, which is satisfactory and indicates there was no interference with the analyte peak from degradation products. Major degradation up to 57% occurred under acidic conditions ([fig. 3a](#F3){ref-type="fig"}). Under alkaline conditions the drug was degraded by approximately 36% ([fig. 3b](#F3){ref-type="fig"}). The drug was approximately 32% degraded under oxi-dizing conditions ([fig. 3c](#F3){ref-type="fig"}). The drug was degraded 15% under thermal condition ([fig. 3d](#F3){ref-type="fig"}) and 30% degradation occurred under photolytic conditions ([fig. 3e](#F3){ref-type="fig"}).

![Chromatogram of forced degradation study. Chromatogrphic profiles of rosuvastatin tablets after subjecting them to (a) acidic, (b) alkaline, (c) oxidative, (d) thermal and (e) photolytic degradation](IJPhS-72-592-g004){#F3}

To determine linearity a calibration graph was obtained by plotting rosuvastatin calcium concentration against peak area. Linearity was good in the concentration range 0.5-80 μg/ml. The regression eqn. was y= 46,956x+85,486 where x is the concentration in μg/ml and y is the peak area in absorbance units; the correlation coefficient was 0.9993.

For assay (n=6) and determination of content uniformity (n=10), RSD for the system precision was 0.45% and 0.37%, respectively, on the same day (intra-day) and 0.41% and 0.55% on dif-ferent days (inter-day). The mean values of method precision (repeatability) were 101.3%, RSD 0.28%, for assay and 101.2%, RSD 0.44%, for content uniformity on the same day (intra-day) and 101.6%, RSD 0.61%, for assay and 101.4%, RSD 0.72%, for content uni-formity on different days (inter-day). Intermediate precision was established by determining the overall (intra-day and inter-day) method precision for assay and determination of content uniformity. For intermediate precision, overall assay value (n=12) was 101.4%, RSD 0.37%, and overall content uniformity (n=20) was 101.4%, RSD 0.64%. The precise result for content uniformity was indicative of uniform distribution of the drug in the tablets without significant variation; this is in accordance with the USP\[[@ref9]\], which stipulates acceptance limits for drug content uniformity and RSD as 85-115 % and \<6 %, respectively.

The accuracy of the method was assessed by determination of recovery for three concentrations covering the range of the method. Known amounts of rosuvastatin calcium (25, 50, and 75 μg/ml) were added to a placebo prepa-ration and the amount of rosuvastatin recovered, in the presence of placebo interference, was calculated. The mean recovery of rosuvastatin calcium was between 99.6 and 101.7%, which is satisfactory ([Table 2](#T2){ref-type="table"}).

###### 

ACCURACY STUDY DATA

![](IJPhS-72-592-g005)

The robustness of the method was assessed by assaying test solutions under different analytical conditions deliber-ately changed from the original condi-tions. For each different analytical condition the standard solution and test solution were prepared separately. The result obtained from assay of the test solution was not affected by varying the conditions and was in accordance with the true value. System suitability data were also found to be satisfactory during variation of the analytical conditions ([Table 3](#T3){ref-type="table"}). The analytical method there-fore remained unaffected by slight but deliberate changes in the analytical conditions.

###### 

ROBUSTNESS STUDY DATA
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During study of the stability of stored solutions of standards and test prepara-tions for assay determination the solu-tions were found to be stable for up to 36 h. Assay values obtained after 36 h were statistically identical with the initial value without measurable loss ([Table 4](#T4){ref-type="table"}).

###### 

SOLUTION STABILITY STUDY DATA
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Before each measurement of valida-tion data a system suitability test was performed by measurement of general characteristics such as peak asymmetry, number of theoretical plates and RSD (%) of peak area observed for a standard solution. The values obtained were satisfactory and in accordance with in-house limits ([Table 5](#T5){ref-type="table"}).

###### 

SYSTEM SUITABILITY DATA
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The intensive approach described in this manuscript was used to develop and validate a liquid chromatographic ana-lytical method that can be used for both assay and determination of content uni-formity of rosuvastatin calcium in a pharmaceutical dosage form. Degradation products produced as a result of stress did not interfere with detection of rosuvastatin calcium and the assay method can thus be regarded as stability indicating.

This HPLC method for assay and determi-nation of content uniformity of rosuvastatin calcium in a tablet formulation was successfully developed and validated for its intended purpose. The method was shown to specific, linear, precise, accu-rate, and robust. Because the method separates rosuvastatin calcium and all the degrada-tion products formed under variety of stress conditions it can be regarded as stability indicating. Because there is no pharmacopeial method for assay and determination of content uniformity of rosuvastatin calcium in pharmaceutical dosage forms, this method is recommended to the industry for quality control of drug content in pharmaceutical preparations.
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